Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsEmerging drugs and vaccines for candidemiaCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentRelevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsIn vitro antifungal activity of isavuconazole against Madurella mycetomatisIsavuconazole: A New Option for the Management of Invasive Fungal Infections.In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisSafety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation studyUncommon opportunistic yeast bloodstream infections from Qatar.Simultaneous determination of propofol and remifentanil in rat plasma by liquid chromatography-tandem mass spectrometry: application to preclinical pharmacokinetic drug-drug interaction analysis.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelIn vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisDevelopments in the treatment of candidiasis: more choices and new challenges.Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.New and investigational triazole agents for the treatment of invasive fungal infections.Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.New generation azole antifungals in clinical investigation.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Azole antifungals: 35 years of invasive fungal infection management.Isavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
P2860
Q26740837-01491C3C-02B1-4CC3-B3EA-81B7B6834188Q26744049-BFFB618A-B69C-4D03-B11F-C256437C20B8Q26828993-ECC52D24-4766-457C-9A83-67189DE089D8Q26863344-D683FE57-F982-4500-AB55-DACB98CAD320Q27025299-FC499FB3-926B-46A2-8E9D-13C5F81AE5F8Q28067726-AAC09D6A-21F9-4A5A-8FA5-3E3365E9C27AQ28082019-08E561D8-44AA-465B-A3C0-171898476AEAQ33763177-D220608F-D8EB-4E1A-9EAD-E7FBFAC9E681Q34298778-F03696ED-B013-4A86-977A-523E4894AC72Q34474946-1DA79558-2564-4059-A73C-69CC681591D6Q34596443-90C93F5E-9D8D-48B0-A492-9B08A3A6867CQ34900399-18DA98CB-AD21-4E4B-A0FE-A681FEFBBCFDQ35076974-D7529764-A4B5-4DB0-B378-61181773CA03Q35168889-67408D8A-7A22-4F6E-9A45-C70887A2F81CQ35189199-6BA92C55-FBC0-4732-BD18-BD216939D4EFQ35194278-F0C8A263-6C79-4389-9A19-A1877E1B20C4Q35385554-6A844A51-5F06-471E-85A8-04B1ADAFB6E3Q35759094-B8F082B6-CD9C-48F3-B779-14443ADDC4AAQ36396166-F7A9FF3A-5FEF-41E4-9106-5198BAB8B65DQ36439102-072A0005-9659-42A0-A7A5-32658E505526Q36623050-043A2A5F-1098-430D-8138-B2C6B7573F2EQ36804054-BE9766B3-55C6-4475-B9D4-5FBAC666B903Q36887855-6673ADC4-5336-48DD-A971-287DB6C15541Q36888052-3F4E6DC2-ED4A-47CA-8769-9ECCE769208EQ37203893-920E38D2-3FB9-4554-869E-663F757CF17EQ37263435-247F17A9-AA77-414E-A02F-20AED9C60785Q37291463-21703E95-8430-408D-812B-D0A86F9CBA2BQ37335649-ABD15C37-328B-4480-8EC6-01ECE02BBCD9Q37364295-37C2FB05-2F24-42A1-B60C-F1ACA11E5792Q37409882-1FDAA234-8417-48CE-9B5D-E0752E3671F1Q37579222-FFEE3B83-D6E4-4107-ADF7-5B14B1BFE002Q37918556-4A17D1C5-7D37-4D3B-A62E-B68798F3058FQ38005226-23DC843B-6923-4921-9759-C1A37C1932CAQ38159688-BE998853-1771-49EA-85B4-1B5D6231FB4FQ38285488-B22B0878-D530-432B-B583-DB1AD723A317Q38406393-A3136390-6204-4629-BB9F-7FF9EB6B957BQ38436002-FA606316-3432-4B44-8FED-86CD2245C6B4Q38534865-30944B79-821D-434A-AB1B-A38527E962B1Q38644817-9AA43FC8-C16E-4985-BBEC-CCB7F4E318A4Q38681635-F32B18B9-1FA1-46A5-A68C-CF456077B77D
P2860
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@en
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@nl
type
label
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@en
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@nl
prefLabel
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@en
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@nl
P2093
P2860
P1476
Single-ascending-dose pharmaco ...... of its prodrug, BAL8557, in h
@en
P2093
Anne Schmitt-Hoffmann
Brigitte Roos
Christoph Beglinger
Erhard Weidekamm
Markus Heep
Michael Roehrle
Michael Schleimer
P2860
P304
P356
10.1128/AAC.50.1.279-285.2006
P407
P577
2006-01-01T00:00:00Z